Tiempo al inicio de quimioradioterapia y su efecto en la supervivencia en cáncer de cérvix
Fecha
2024
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
ANTECEDENTES: El cáncer de cérvix es el cuarto diagnóstico más común a nivel
mundial, siendo causa importante mortalidad, el carcinoma escamocelular es el subtipo
histológico de mayor frecuencia y su diagnóstico se lo realiza en etapa localmente avanzada,
el tratamiento estándar es la quimioradioterapia que se debe iniciar en un lapso no mayor a
60 días. OBJETIVO: Determinar el intervalo de tiempo entre el diagnóstico y el inicio del
tratamiento de quimio radioterapia y su efecto supervivencia global en mujeres con cáncer
de cérvix. METODOLOGÍA: Se realizó un estudio observacional, descriptivo y
transversal, en mujeres con cáncer de cuello de útero atendidas en el periodo comprendido
entre enero de 2015 y diciembre de 2019 y recibieron tratamiento con quimioradioterapia.
RESULTADO: De 1790 pacientes se estimó una muestra de 365 pacientes, la supervivencia
global a 5 años es del 46.5%. Al contrastar con el tiempo en el inicio del tratamiento, el
análisis univariable y multivariable revelo una relación estadísticamente significativa hacia
el inicio de tratamiento menor a 6 semanas [HR 1.87(IC 95% 1.02-3.40)] y p 0.04 frente a
recibir tratamiento mayor de 6 semanas y se mantiene junto al menor estadio clínico IIB.
CONCLUSIONES: El inicio de tratamiento menor a 6 semanas y el estadio clínico IIB son
los factores asociados a mejor supervivencia, estos deben ser considerados durante el
régimen terapéutico.
BACKGROUND: Cervical cancer is the fourth most common diagnosis worldwide, being a significant cause of mortality. Squamous cell carcinoma is the most common histological subtype and its diagnosis is made in a locally advanced stage. The standard treatment is chemoradiotherapy, which must be initiated. in a period of no more than 60 days. OBJECTIVE: To determine the time interval between diagnosis and the start of chemotherapy and radiotherapy treatment and its overall survival effect in women with clinical stage IIB-VA cervical cancer. METHODOLOGY: An observational, descriptive and cross-sectional study was carried out in women with cervical cancer treated in the period between January 2015 and December 2019 and received treatment with chemoradiotherapy. RESULTS: Of 1790 patients, a sample of 365 patients was estimated, the overall survival at 5 years is 46.5%. When contrasted with the time at the start of treatment, the univariate and multivariate analysis revealed a statistically significant relationship towards the start of treatment less than 6 weeks [HR 1.87 (95% CI 1.02-3.40)] and p 0.04 versus receiving treatment longer than 6 weeks and remains next to the lowest clinical stage IIB. CONCLUSIONS: The start of treatment less than 6 weeks and clinical stage IIB are the factors associated with better survival; these must be considered during the therapeutic regimen
BACKGROUND: Cervical cancer is the fourth most common diagnosis worldwide, being a significant cause of mortality. Squamous cell carcinoma is the most common histological subtype and its diagnosis is made in a locally advanced stage. The standard treatment is chemoradiotherapy, which must be initiated. in a period of no more than 60 days. OBJECTIVE: To determine the time interval between diagnosis and the start of chemotherapy and radiotherapy treatment and its overall survival effect in women with clinical stage IIB-VA cervical cancer. METHODOLOGY: An observational, descriptive and cross-sectional study was carried out in women with cervical cancer treated in the period between January 2015 and December 2019 and received treatment with chemoradiotherapy. RESULTS: Of 1790 patients, a sample of 365 patients was estimated, the overall survival at 5 years is 46.5%. When contrasted with the time at the start of treatment, the univariate and multivariate analysis revealed a statistically significant relationship towards the start of treatment less than 6 weeks [HR 1.87 (95% CI 1.02-3.40)] and p 0.04 versus receiving treatment longer than 6 weeks and remains next to the lowest clinical stage IIB. CONCLUSIONS: The start of treatment less than 6 weeks and clinical stage IIB are the factors associated with better survival; these must be considered during the therapeutic regimen
Descripción
PDF
Palabras clave
NEOPLASIAS DE CABEZA Y CUELLO, QUIMIORRADIOTERAPIA, MORTALIDAD, HOSPITAL SOLCA DE GUAYAQUIL, ECUADOR